ENXTPA:ABVXBiotechs
ABIVAX Société Anonyme (ENXTPA:ABVX) Could Be 44% Undervalued As UC Data Lands
Abivax Société Anonyme (ENXTPA:ABVX) is back in focus after releasing new ABTECT Maintenance Part 2 data on its ulcerative colitis candidate obefazimod, followed closely by a large follow on equity offering.
See our latest analysis for ABIVAX Société Anonyme.
The latest data and capital raise have arrived after a steep run in ABIVAX Société Anonyme, with a 30 day share price return of 42.89% and a very large 1 year total shareholder return that signals strong momentum from earlier stages in...